Tumor Biology

, Volume 34, Issue 4, pp 2275–2281 | Cite as

Peroxiredoxin III protein expression is associated with platinum resistance in epithelial ovarian cancer

  • Xin-yan Wang
  • Hai-jiao Wang
  • Xiu-qin Li
Research Article


We investigated the association between peroxiredoxin III (PRX III) and chemotherapy resistance in ovarian cancer. Patient’s specimens were taken at the time of surgery. Determination of resistance is based on whether first diagnosis of relapse occurred within 6 months after the cessation of chemotherapy. PRX III expression was immunohistochemically determined in paraffin-embedded specimens from platinum-resistant (Pt-resistant) and platinum-sensitive (Pt-sensitive) patients. The Pt-resistant group had significantly higher PRX III protein compared to the Pt-sensitive group. The two groups showed no significant differences in pathological classification and age, although they differed significantly in tissue differentiation and stage. PRX III protein was significantly higher in the Pt-resistant serous carcinomas, in moderately and poorly differentiated, and in stage III and IV ovarian cancer tissues compared to the Pt-sensitive group. PRX III may be associated with drug resistance in ovarian cancer.


PRX III Epithelial ovarian cancer Chemotherapy Immunohistochemistry Cisplatin 


Conflicts of interest



  1. 1.
    Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61:212–36.PubMedCrossRefGoogle Scholar
  2. 2.
    Sourbier C. Ovarian cancer: emerging molecular-targeted therapies. Biologics. 2012;6:147–54.PubMedGoogle Scholar
  3. 3.
    Davidson B, Trope CG, Reich R. Epithelial-mesenchymal transition in ovarian carcinoma. Front Oncol. 2012;2:33.PubMedCrossRefGoogle Scholar
  4. 4.
    Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer. 2003;3:502–16.PubMedCrossRefGoogle Scholar
  5. 5.
    NCCN. NCCN clinical practice guideline in oncology: ovarian cancer including fallopian tube cancer and primary peritoneal cancer. Fort Washington: NCCN; 2013.Google Scholar
  6. 6.
    Godwin AK, Meister A, O’Dwyer PJ, Huang CS, Hamilton TC, Anderson ME. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA. 1992;89:3070–4.PubMedCrossRefGoogle Scholar
  7. 7.
    Henkels KM, Turchi JJ. Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines. Cancer Res. 1999;59:3077–83.PubMedGoogle Scholar
  8. 8.
    Yan X, Fraser M, Qiu Q, Tsang BK. Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner. Gynecol Oncol. 2006;102:348–55.PubMedCrossRefGoogle Scholar
  9. 9.
    Krieger ML, Eckstein N, Schneider V, Koch M, Royer HD, Jaehde U, et al. Overcoming cisplatin resistance of ovarian cancer cells by targeted liposomes in vitro. Int J Pharm. 2010;389:10–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003;22:7265–79.PubMedCrossRefGoogle Scholar
  11. 11.
    Masuda H, Tanaka T, Takahama U. Cisplatin generates superoxide anion by interaction with DNA in a cell-free system. Biochem Biophys Res Commun. 1994;203:1175–80.PubMedCrossRefGoogle Scholar
  12. 12.
    Klaunig JE, Xu Y, Isenberg JS, Bachowski S, Kolaja KL, Jiang J, et al. The role of oxidative stress in chemical carcinogenesis. Environ Health Perspect. 1998;106 Suppl 1:289–95.PubMedCrossRefGoogle Scholar
  13. 13.
    Chae HZ, Robison K, Poole LB, Church G, Storz G, Rhee SG. Cloning and sequencing of thiol-specific antioxidant from mammalian brain: alkyl hydroperoxide reductase and thiol-specific antioxidant define a large family of antioxidant enzymes. Proc Natl Acad Sci USA. 1994;91:7017–21.PubMedCrossRefGoogle Scholar
  14. 14.
    Hofmann B, Hecht HJ, Flohe L. Peroxiredoxins. Biol Chem. 2002;383:347–64.PubMedGoogle Scholar
  15. 15.
    Wood ZA, Schroder E, Robin Harris J, Poole LB. Structure, mechanism and regulation of peroxiredoxins. Trends Biochem Sci. 2003;28:32–40.PubMedCrossRefGoogle Scholar
  16. 16.
    Song IS, Kim HK, Jeong SH, Lee SR, Kim N, Rhee BD, et al. Mitochondrial peroxiredoxin III is a potential target for cancer therapy. Int J Mol Sci. 2011;12:7163–85.PubMedCrossRefGoogle Scholar
  17. 17.
    Karihtala P, Mantyniemi A, Kang SW, Kinnula VL, Soini Y. Peroxiredoxins in breast carcinoma. Clin Cancer Res. 2003;9:3418–24.PubMedGoogle Scholar
  18. 18.
    Lehtonen ST, Svensk AM, Soini Y, Paakko P, Hirvikoski P, Kang SW, et al. Peroxiredoxins, a novel protein family in lung cancer. Int J Cancer. 2004;111:514–21.PubMedCrossRefGoogle Scholar
  19. 19.
    Quan C, Cha EJ, Lee HL, Han KH, Lee KM, Kim WJ. Enhanced expression of peroxiredoxin I and VI correlates with development, recurrence and progression of human bladder cancer. J Urol. 2006;175:1512–6.PubMedCrossRefGoogle Scholar
  20. 20.
    Cha MK, Suh KH, Kim IH. Overexpression of peroxiredoxin I and thioredoxin1 in human breast carcinoma. J Exp Clin Cancer Res. 2009;28:93.PubMedCrossRefGoogle Scholar
  21. 21.
    Kinnula VL, Lehtonen S, Sormunen R, Kaarteenaho-Wiik R, Kang SW, Rhee SG, et al. Overexpression of peroxiredoxins I, II, III, V, and VI in malignant mesothelioma. J Pathol. 2002;196:316–23.PubMedCrossRefGoogle Scholar
  22. 22.
    Chung YM, Yoo YD, Park JK, Kim YT, Kim HJ. Increased expression of peroxiredoxin II confers resistance to cisplatin. Anticancer Res. 2001;21:1129–33.PubMedGoogle Scholar
  23. 23.
    Zhang B, Su Y, Ai G, Wang Y, Wang T, Wang F. Involvement of peroxiredoxin I in protecting cells from radiation-induced death. J Radiat Res. 2005;46:305–12.PubMedCrossRefGoogle Scholar
  24. 24.
    Choi JH, Kim TN, Kim S, Baek SH, Kim JH, Lee SR, et al. Overexpression of mitochondrial thioredoxin reductase and peroxiredoxin III in hepatocellular carcinomas. Anticancer Res. 2002;22:3331–5.PubMedGoogle Scholar
  25. 25.
    Noh DY, Ahn SJ, Lee RA, Kim SW, Park IA, Chae HZ. Overexpression of peroxiredoxin in human breast cancer. Anticancer Res. 2001;21:2085–90.PubMedGoogle Scholar
  26. 26.
    Nonn L, Berggren M, Powis G. Increased expression of mitochondrial peroxiredoxin-3 (thioredoxin peroxidase-2) protects cancer cells against hypoxia and drug-induced hydrogen peroxide-dependent apoptosis. Mol Cancer Res. 2003;1:682–9.PubMedGoogle Scholar
  27. 27.
    Chang TS, Cho CS, Park S, Yu S, Kang SW, Rhee SG. Peroxiredoxin III, a mitochondrion-specific peroxidase, regulates apoptotic signaling by mitochondria. J Biol Chem. 2004;279:41975–84.PubMedCrossRefGoogle Scholar
  28. 28.
    Jurisicova A, Jurisica I, Kislinger T. Advances in ovarian cancer proteomics: the quest for biomarkers and improved therapeutic interventions. Expert Rev Proteomics. 2008;5:551–60.PubMedCrossRefGoogle Scholar
  29. 29.
    Wonsey DR, Zeller KI, Dang CV. The c-Myc target gene PRDX3 is required for mitochondrial homeostasis and neoplastic transformation. Proc Natl Acad Sci USA. 2002;99:6649–54.PubMedCrossRefGoogle Scholar
  30. 30.
    Li XQ, Zhang SL, Cai Z, Zhou Y, Ye TM, Chiu JF. Proteomic identification of tumor-associated protein in ovarian serous cystadenocarinoma. Cancer Lett. 2009;275:109–16.PubMedCrossRefGoogle Scholar
  31. 31.
    Kim K, Yu M, Han S, Oh I, Choi YJ, Kim S, et al. Expression of human peroxiredoxin isoforms in response to cervical carcinogenesis. Oncol Rep. 2009;21:1391–6.PubMedGoogle Scholar
  32. 32.
    Chua PJ, Lee EH, Yu Y, Yip GW, Tan PH, Bay BH. Silencing the peroxiredoxin III gene inhibits cell proliferation in breast cancer. Int J Oncol. 2010;36:359–64.PubMedGoogle Scholar
  33. 33.
    Su DM, Zhang Q, Wang X, He P, Zhu YJ, Zhao J, et al. Two types of human malignant melanoma cell lines revealed by expression patterns of mitochondrial and survival-apoptosis genes: implications for malignant melanoma therapy. Mol Cancer Ther. 2009;8:1292–304.PubMedCrossRefGoogle Scholar
  34. 34.
    Jarvela S, Rantala I, Rodriguez A, Kallio H, Parkkila S, Kinnula VL, et al. Specific expression profile and prognostic significance of peroxiredoxins in grade II-IV astrocytic brain tumors. BMC Cancer. 2010;10:104.PubMedCrossRefGoogle Scholar
  35. 35.
    Park JH, Kim YS, Lee HL, Shim JY, Lee KS, Oh YJ, et al. Expression of peroxiredoxin and thioredoxin in human lung cancer and paired normal lung. Respirology. 2006;11:269–75.PubMedCrossRefGoogle Scholar
  36. 36.
    Vivas-Mejia PE, Ozpolat B, Chen X, Lopez-Berestein G. Downregulation of the c-Myc target gene, peroxiredoxin III, contributes to arsenic trioxide-induced apoptosis in acute promyelocytic leukemia. Int J Cancer. 2009;125:264–75.PubMedCrossRefGoogle Scholar
  37. 37.
    Liu X, Feng R, Du L. The role of enoyl-CoA hydratase short chain 1 and peroxiredoxin 3 in PP2-induced apoptosis in human breast cancer MCF-7 cells. FEBS Lett. 2010;584:3185–92.PubMedCrossRefGoogle Scholar
  38. 38.
    Pak JH, Choi WH, Lee HM, Joo WD, Kim JH, Kim YT, et al. Peroxiredoxin 6 overexpression attenuates cisplatin-induced apoptosis in human ovarian cancer cells. Cancer Invest. 2011;29:21–8.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  1. 1.Department of Gynecology and ObstetricsShengjing Hospital of China Medical UniversityShenyangChina
  2. 2.Department of Gynecology and ObstetricsBenxi Center Hospital of China Medical UniversityBenxiChina

Personalised recommendations